new glp 1 drug retatrutide Promises Big Weight Loss, but Safety Remains a Question Back in 2023 we saw

Soft tissue facial changes following massive weight loss secondary to medical and surgical bariatric interventions: a systematic review

After switching from Tirzepatide to Retatrutide, the timeline may vary depending on your starting dose

Notably, there were no hepatic decompensations or increased side effects in the semaglutide group, suggesting that GLP-1 agonists are likely safe in compensated cirrhosis

Patients should seek urgent medical advice if hair loss is accompanied by scalp pain, redness, scaling, or complete bald patches

States will announce participation decisions in mid-2026

Research-only supply (21+) Products are supplied strictly for laboratory research use